CRO/Sponsor

Clinical Trial Supply Chain

Decentralized Clinical Trials

Early Phase Development

Investigative Sites

Protocol Design

Risk-Based Monitoring

Study Start-Up

Trial Design

Clinical Operations & Strategy

Diversity Action Plans

Industry Initiatives

Recruitment

Analytics

Electronic Data Capture

Metrics & Benchmarks

Real World Evidence

Data Management

CRAACO

Enrollment

Integrated Research

Patient Participation

Institutional Review Board & Ethics Committee

Regulatory

Artificial Intelligence/Machine Learning

eClinical

mHealth

Technology

News

Academy

Publications

All Publications

E-Books

Media

Editorial Podcasts

Editorial Videos

Peer Exchange

Practice Academy

Conferences

Conference Coverage

Conference Listing

Columns

All Columns

A Closing Thought

Clinical Trial Insights

View from Brussels

View from Washington

Resources

Advertise

Blogs

Events

Front & Center

Partner Perspectives

White Papers

Webcasts

Subscribe

Applied Clinical Trials is the thought leader in pharmaceutical drug development operations and clinical trial design, management, and monitoring.

About

Contact Us

Editorial Contacts

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Applied Clinical Trials Online

LinkedIN

Instagram

Facebook

Youtube

Soundcloud

Threads

Spotlight

DE&I

Topic

1rem

How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.

Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma

As wearable ECG technology advances, cardiac safety studies in clinical trials are evolving to capture richer, continuous heart data while reducing patient burden.

The Future of Cardiac Safety: How Wearable ECGs Enhance Patient Monitoring in Drug Trials

In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs are evolving beyond testing to become strategic partners in clinical trial success.

How Central Labs Are Powering Decentralized and Hybrid Clinical Trials

Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving meaningful impact for patients. 

Digital Measures of Health: What’s in it for Patients? 

Clinical trial liaisons rather serve as experts in their therapeutic areas and as clinical trial specialists to provide a suite of strategic advantages to benefit a study.

The Value of Clinical Trial Liaisons in the Drug Development Lifecycle

In this video interview, Daniel McAllister, Kyle McAllister, co-founder, CEO, Trially, discusses how clinical trial sites and sponsors are responding to funding constraints by turning to telemedicine, cost-containment strategies, and increased reliance on industry-sponsored research.

How Sites and Sponsors Are Adapting to Clinical Trial Budget Cuts

, Kyle McAllister, co-founder, CEO, Trially, discussed the impact of funding cuts on underrepresented populations in medical research, emphasizing the importance of diversity-focused research. He highlighted the challenges created by budget cuts, particularly in patient recruitment and retention, due to reduced support staff. McAllister noted that artificial intelligence (AI) and new technologies like telemedicine are crucial for addressing these challenges by automating tasks and improving efficiency. He provided examples of AI's success in reducing chart review time and increasing patient enrollment in studies.

ACT: How are clinical trial sites and sponsors adapting to these constraints?

Ultimately, they're doing more with less, like I said before, they're resource constrained, and they're doing more with less, which looks like a lot of things, but it's leveraging new technologies like telemedicine or other tools that could decrease the cost of the actual care being provided, so cost containment measures, using remote monitoring tools, using teams that didn't previously work together across multiple types of studies or departments. We've seen sites turning more towards industry sponsored trials to drive more revenue and ultimately cover some of the research they're doing that was NIH and other government funded research, essentially using pharma money to keep the lights on and keep things moving forward. Not all that's terrible, like the idea of moving towards more efficiency and finding ways to drive more revenue to keep things more sustainable, there's some positive things in that, but I think the one of the big potential conflicts is it creates is a lot of the shift towards more industry sponsored research means the institutional priorities being shifted away from public interest focused research. Like I said, there's some pro in that, but there's also some real conflict and concern.

I think the brutal reality for a lot of sites is they're being forced to adapt in ways that aren't great, like they're having to cut staff, they're having to close departments, they're having to close research programs. I think there is a lot of, I'll say, research capacity that disappears with that, that it's going to take time to grow back. There's just research capacity that can't be covered, and we're in an age where it's easier and easier to find new molecules, find new things to do research on, and this infrastructure that was there to actually run that research is being whittled back. Sites are doing heroic work out there, but I worry that heroism isn't a sustainable staffing model.

Videos

In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how clinical trial sites and sponsors are responding to funding constraints by turning to telemedicine, cost-containment strategies, and increased reliance on industry-sponsored research.

In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer Network (NCCN), explores how emerging technologies such as wearable devices, real-world data analysis, and decentralized trial designs can improve the identification and engagement of potential cancer clinical trial participants.

Leveraging Technology to Enhance Cancer Clinical Trial Recruitment

, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer Network (NCCN), discussed the current state and challenges of cancer patient participation in clinical trials. Barriers to participation can include lack of understanding, economic burdens, and implicit biases. Robinson highlighted solutions such as increased education, legislation like the Clinical Trials Modernization Act, and engaging patients early in trial design. He also touched on the use of technology, such as biomarker testing and wearable devices, which can also enhance recruitment and reduce burdens.

ACT: In what ways can technology be utilized to identify and engage potential cancer trial participants more effectively?

This is actually a really exciting topic to me, because I think we are in an era where we can truly engage technology to help answer these kinds of questions. As I mentioned earlier, trials are becoming more and more complex because of the targeted therapies that we're testing in them, so using the kinds of modalities and technology that is available now for biomarker testing, real-world evidence, so large dataset analysis to really understand what patients have an opportunity to respond to these targeted therapies, etc. and you can sort of hone in on them, on those patients for trying to recruit them, is important. I think technology can also be used to address these economic and time burdens as well. When you think about smart watches, cell phone apps, wearable devices, a lot of the time and economic burden comes from patients having to travel back for extra scans, extra lab tests, those sorts of things. You can envision ways in which that technology can be used to supplement or take the place of those tests. Similarly, you can use in home testing to reduce travel time, to decentralize the trial designs. I think you could even take advantage of technology for developing better educational materials as well, so lots of opportunity, and I think it's an area of active research.

mHealth

Latest News